Tobira takes on three execs
This article was originally published in Scrip
Tobira Therapeutics has completed its senior management team with three hires. Joining the company are Caroline Loewy as executive vice president and chief financial officer, Dr Jeff Enejosa as senior director of clinical research, and Mark Menning as director of pharmaceutical sciences. Ms Loewy's prior positions include CFO of two publicly-held biotechnology companies and a Wall Street equity research analyst. Dr Enejosa was director, clinical research at Gilead Sciences. Mr Menning most recently served as senior research scientist, formulation and process development, at Gilead Sciences.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.